Cellectis Announces Launch of Follow-On Offering
02 févr. 2023 16h01 HE
|
Cellectis Inc.
NEW YORK, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Cellectis S.A. (“Cellectis” or the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering...
Cellectis Amends $20 Million Convertible Note Under Collaboration Agreement with its Partner Cytovia Therapeutics
20 janv. 2023 16h30 HE
|
Cellectis Inc.
NEW YORK, Jan. 20, 2023 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to...
Calyxt and Cibus Announce the Signing of a Definitive Merger Agreement
17 janv. 2023 07h10 HE
|
Cellectis Inc.
NEW YORK, Jan. 17, 2023 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biotechnology company using its gene editing platform to deliver life-saving cell and...
NKGen Biotech Appoints Paul Y. Song, MD as Chief Executive Officer
10 janv. 2023 13h27 HE
|
NKGen Biotech
SANTA ANA, Calif., Jan. 10, 2023 (GLOBE NEWSWIRE) -- NKGen Biotech, a biotechnology company harnessing the power of the body’s immune system through the development of natural killer cell therapies,...
Calidi Biotherapeutics and First Light Acquisition Group (FLAG) Announce Merger Agreement to Create a Publicly Listed, Clinical-Stage Biotechnology Company Utilizing Stem Cell-Based Platforms to Revolutionize Oncolytic Virotherapies
09 janv. 2023 10h33 HE
|
First Light Acquisition Group; Calidi Biotherapeutics, Inc.
-Total gross proceeds from transaction, before payment of transaction expenses, expected to be up to $82 million assuming no redemptions, combining a possible PIPE financing of up to $40 million and...
Cellectis secures a €40 million credit facility from the European Investment Bank to support its Research, Development and Innovation activities
28 déc. 2022 16h30 HE
|
Cellectis Inc.
The credit facility will enable Cellectis to support the development of its UCART product candidates pipelineThe credit facility consists of three tranches of €20 million, €15 million, and €5 million...
Monthly information on share capital and company voting rights
16 déc. 2022 16h30 HE
|
Cellectis Inc.
NEW YORK, Dec. 16, 2022 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal number of sharesin the capitalTotal number of...
Celyad Oncology Announces Third Quarter 2022 Financial Results and Recent Business Highlights
10 nov. 2022 01h01 HE
|
Celyad Oncology SA
Company continues to transition business focus to monetizing unique cell therapy intellectual property and prioritizing R&D discoveryClinical updates expected by end of year for the Phase 1...
Monthly information on share capital and company voting rights
08 nov. 2022 16h30 HE
|
Cellectis Inc.
NEW YORK, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal number of sharesin the capitalTotal number of voting...
NKGen Biotech Receives IND Clearance from FDA for SNK02 Allogeneic Natural Killer Cell Therapy for Solid Tumors
17 oct. 2022 14h27 HE
|
NKGen Biotech
SANTA ANA, Calif., Oct. 17, 2022 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc., a biotechnology company harnessing the power of the body’s immune system through the development of natural killer (NK) cell...